



(51) International Patent Classification:

A61K 39/395 (2006.01) *A61K 31/496* (2006.01)
A61K 47/48 (2006.01) *A61P 35/00* (2006.01)
C07K 17/06 (2006.01)

(21) International Application Number:

PCT/US2015/036414

(22) International Filing Date:

18 June 2015 (18.06.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/014,912 20 June 2014 (20.06.2014) US
 62/015,661 23 June 2014 (23.06.2014) US

(71) Applicants: **ABGENOMICS INTERNATIONAL INC.**
 [US/US]; 3500 South DuPont Highway, Dover, DE 19901
 (US). **BIOALLIANCE C.V.** [NL/NL]; Oudegracht 202,
 1811CR Alkmaar (NL).

(72) Inventors: **LIN, Rong-Hwa**; 4201 G Juniper Lane Unit G,
 Palo Alto, CA 94306 (US). **LIN, Shih-Yao**; 7F., No. 1,
 Lane 105, Lishan Street, Neihu District, Taipei (TW).
HSIEH, Yu-Chi; 12F., No. 54, Dongshi Street, Xizhi Dis-
 trict, New Taipei City 221 (TW). **HUANG, Chiu-Chen**;
 4F., No. 2, Lane 339, Section 2, Neihu Road, Neihu Dis-

trict, Taipei (TW). **LEE, Shu-Hua**; 5F., No. 136, Lane 91,
 Section 1, Neihu Road, Neihu District, Taipei (TW). **TSAI,**
Yu-Ying; 3F., No. 7, Alley 15, Lane 121, Jinghua Street,
 Wenshan District, Taipei City 116 (TW).

(74) Agent: **EL-HAYEK, Roque**; Wolf, Greenfield & Sacks,
 P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (*unless otherwise indicated, for every
 kind of national protection available*): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
 kind of regional protection available*): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: HER2 ANTIBODY-DRUG CONJUGATES




Figure 4

(57) Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleaved under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker. In some aspects of the present disclosure, the targeting moiety is an anti-HER2 antibody. The present disclosures further provide compositions and methods for treating cancers.



Published:

— *with international search report (Art. 21(3))*